Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants Aged 2 Months (at Least 6 Weeks) and 3 Months

NCT05759520 is registered in ClinicalTrials.gov with Fosun Adgenvax Biopharmaceutical Co.,Ltd. as lead sponsor.

NCT NCT05759520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants Aged 2 Months (at Least 6 Weeks) and 3 Months
Lead sponsor
Fosun Adgenvax Biopharmaceutical Co.,Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 4, 2022
Completion date
June 30, 2025
Enrollment
1,800 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

streptococcus pneumoniae infection